trial

Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis

NCTId NCT01878513
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 88 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2018-07-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
88 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-09-23
Primary completion
2018-07-31
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor

Investigators

1
Jianping Zhang, MD, PhDPrincipal Investigator

Sites

1 total
Glen Oaks, United States

Facts & assertions

4 sourced
Enrollment
88
Phase
NA
Primary Completion Date
2018-07-31
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
indication
Psychotic Disorder Not Otherwise Specified
indication
Schizoaffective Disorder
indication
Severe Bipolar Disorder With Psychotic Features
indication
investigator
Jianping Zhang, MD, PhD
person